RBD immunogen
SARS-CoV-2 Spike protein Receptor Binding Domain used for immunization.
General information
RBD immunogen refers to various experimental protein preparations which elicit immune response based on SARS-CoV-2 Spike RBD presentation.
The recombinant RBD domain or RBD/mouse IgG1-Fc fusion protein was used experimentally to induce immune response by Zang et al. (2020) or to elicit lasting neutralizing antibody response in mice, optimally when adjuvanted with Zn-chitosan, by Srivastava et al. (2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
Spike protein Protein factor Animal model In vitro |
BALB/c mice; in vitro assays | 6.26 | The SARS-CoV-2 spike protein recombinant RBD domain or RBD/mouse IgG1-Fc fusion protein was used to immunize mice. The anti-sera from immunized mice were found to react with RBD, competitively inhibit ACE2-RBD binding and neutralized SARS-CoV-2 pseudovirus in vitro without antibody-dependent enhancement. |
Sep/03/2020 |
|
Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen
Spike protein Protein factor Animal model In vitro |
in vitro binding assay; Vero E6 cells; female BALB/c mice; SARS CoV-2 (ATCC CRL-1586) | 5.09 | The recombinant protein domain with conserved glycosylation and disulphide bridge sites was used as an immunogen. It was adjuvanted with a spectrum of formulations. After three rounds of vaccination in mice, high titres of RBD-binding and virus-neutralizing antibodies were detected. The likely protective effect persisted during the full observation period and was most potent when Zn-chitosan was used as an adjuvant. |
Mar/11/2021 |
